scholarly journals Management of cancer of unknown primary

2020 ◽  
Vol 48 (2-3) ◽  
pp. 85-88
Author(s):  
Iva Andrašek ◽  
◽  
Mirna Ravlić ◽  
Martina Mikulandra ◽  
Franjo Cmrečak ◽  
...  
Keyword(s):  
Metastatic Tumor ◽  
Cancer Of Unknown Primary ◽  
Primary Site ◽  
Unknown Primary ◽  
Combined Modality Treatment ◽  
Tumor Type ◽  
Patients With Cancer ◽  
Poorly Differentiated ◽  
Primary Origin ◽  
Chemotherapy Agents

Cancer of an unknown primary site is most commonly an aggressive metastatic tumor with a median patient survival of 6 to 9 months. Histologically, it is predominantly adenocarcinoma, and if the primary site is subsequently diagnosed, it is usually the pancreas or lung. Biopsy should be performed whenever possible to classify a tumor of unknown primary origin into one of the following entities: adenocarcinoma, poorly differentiated carcinoma with characteristics similar to adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma, poorly differentiated neoplasm. After determining the primary tumor type, the subtype is determined by immunohistochemical staining. In oligometastatic disease, there is a possibility of surgical treatment. Radiotherapy is used as a part of combined modality treatment. Most patients with cancer of unknown primary have an unfavorable prognosis despite multiple chemotherapy agents, and no protocol can be recommended as standard therapy.

Symptom assessment in patients with cancer of unknown primary site.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e20696-e20696
Author(s):  
Benjamin Scheier ◽  
Alexander T. Pearson ◽  
Joshua Murray Wilfong ◽  
Laurence H. Baker
Keyword(s):  
Symptom Assessment ◽  
Cancer Of Unknown Primary ◽  
Primary Site ◽  
Unknown Primary ◽  
Unknown Primary Site ◽  
Patients With Cancer

scholarly journals Cancer of Unknown Primary Site Syndrome‐CUP Syndrome - Diagnostic and Therapeutical Dillemas

2014 ◽  
Vol 31 (2) ◽  
pp. 87-94 ◽  
Author(s):  
Ivica Pejčić ◽  
Svetislav Vrbić ◽  
Mirjana Todorović ◽  
Ivan Petković ◽  
Mirjana Balić ◽  
...  
Keyword(s):  
Diagnostic Techniques And Procedures ◽  
Basic Research ◽  
Diagnostic Techniques ◽  
Cancer Of Unknown Primary ◽  
Primary Site ◽  
New Drugs ◽  
Unknown Primary ◽  
Disease Treatment ◽  
Primary Origin ◽  
Disseminated Disease

Summary Metastatic carcinomas of unknown primary origin (cancer of unknown primary-CUP) represent 3-5% of all cancers. This term includes all patients presented with metastatic disease in whom the primary site could not have been identified. Despite the use of modern and comprehensive diagnostic techniques and procedures, there is no improvement in efficacy (efficiency) of indentifying the primary site of disseminated disease. That is why a diagnostic procedure should be rational and should include the basic diagnostic examination (analyses) with the aim to define biological and clinical characteristics of diagnosed disease, as well as an optimal therapeutic approach. Although the overall prognosis of the majority of these patients is poor, it is possible, nowadays, to distinguish the subgroups of patients with favorable prognosis. Results of new basic research, better understanding of pathogenesis at the molecular level and introduction of new drugs through clinical trials suggest an advance in this disease treatment and outcome.

Diagnostic Imaging Efficacy In Metastases From Unknown Primary Site – Own Material

2015 ◽  
Vol 87 (5) ◽  
Author(s):  
Angelika Bara ◽  
Piotr Pluta ◽  
Arkadiusz Jeziorski
Keyword(s):  
Clinical Investigation ◽  
Cancer Of Unknown Primary ◽  
Primary Site ◽  
Unknown Primary ◽  
Study Group ◽  
Favorable Prognosis ◽  
Metastatic Lesions ◽  
Neoplastic Lesion ◽  
Primary Origin ◽  
Unknown Primary Origin

AbstractCancer of Unknown Primary Origin (CUPO) is defined by the presence of metastatic lesions, diagnosed by means of cytological or pathological evaluation, for which no primary site can be detected during a thorough examination. The clinical investigation, directed at locating the site of the neoplastic lesion, is determined by the results of laboratory tests, imaging procedures, and pathological examinations. It is also essential to conduct a complete medical history and thorough physical examination. The detection of the primary site allowed to introduce specific therapy, which can offer clinical benefits, considering a favorable prognosis.was to assess the range of diagnostic procedures performed in patients with CUPO and efficacy in identifying the primary lesion.Retrospective analysis comprised a group of 29 patients with CUPO, operated between January, 2002 and December, 2011, at the Department of Surgical Oncology, Medical University in Łódź. The study group comprised 16 male and 13 female patients; median age at presentation was 58.3 years (ranging between 30-79 years).Detailed diagnostic management depending on the location of metastatic lesions and their histological type was performed in 20 of the 29 study patients (69%). Considering the remaining 9 (31%) patients detailed diagnostics was not performed, due to the patients' poor general condition. In 55% (11/20) of patients subject to detailed diagnostics, the primary neoplastic lesion was determined.Considering the study group, most patients with cancer of unknown primary origin were characterized by a favorable prognosis, which justified thorough diagnostics, in order to establish the primary neoplastic lesion. The introduction of diagnostic examinations enabled to identify the primary site of the tumor in more than 50% of patients. With the development of imaging methods one can expect improvement of unsatisfactory results, considering the detection of primary neoplastic foci.

Sign in / Sign up

Export Citation Format

Share Document